We're raising our price target on Cardinal Health after another stellar quarter of profits

Cardinal Health reported fiscal 2027 Q1 revenue of $67.51 billion, up 4% year over year and above $66.6 billion consensus, while adjusted EPS rose 28% to $3.26 versus $2.94 expected. The company raised full-year adjusted EPS guidance to $12.80-$13.00 from $12.40-$12.60; shares gained more than 3% Thursday. Pharmaceutical and Specialty Solutions exceeded expectations, while the smaller Other segment missed on revenue and operating profit, and Global Medical Products and Distribution operating profit fell 28% year over year to $33 million. Cardinal repurchased $500 million of stock during the quarter.

Analysis

The key change is not distributor volume but mix and earnings quality: specialty therapeutics and practice-management services can make incremental growth more valuable than the traditional, thin-margin drug-distribution base. That supports a higher-quality earnings narrative for CAH, but the quarter does not yet establish that newer businesses are scaling smoothly: the strategically important Other segment missed, while Global Medical Products remains exposed to input costs. If those disappointments persist, the market may be capitalizing a transformation before it is visible in segment profits.

Near term, a post-print rally after a record close raises the risk that good execution is already reflected in the price; the raised outlook is constructive, not a reason to extrapolate indefinitely. Over 1–3 months, watch specialty growth, Other-segment profit delivery, and the next guidance update. Over 6–18 months, MSO integration and any acquisitions could broaden growth, but also add execution and capital-allocation risk. CVS’s planned separation may complicate future purchasing dynamics, although management says the current agreement continues beyond the 2028 separation; this is a watch item, not an immediate contract-loss thesis. The positive peer backdrop at Cencora and McKesson suggests industry demand strength rather than an obvious CAH-specific share win. Falsification: a cut to pharma profit-growth guidance, repeated Other-segment misses, or renewed deterioration in medical-products profit would weaken the quality-upgrade thesis.

Key Decisions for Investors

• Do not chase the immediate post-earnings strength. For existing CAH exposure, consider trimming into further sharp gains if the position has become oversized; the upside case now depends on delivery beyond the raised outlook, while segment execution remains uneven.
• Keep CAH on a pullback watchlist rather than initiating a valuation-blind position. Reassess after evidence that Other-segment profit growth and specialty momentum are translating into sustained results; verify valuation versus its own history and peers before sizing.
• Do not treat CVS’s separation announcement as an imminent CAH contract catalyst. Monitor transition disclosures and any changes to procurement arrangements ahead of the 2028 separation; a disclosed renewal disruption would invalidate the benign read-through.
• Track CAH’s next quarterly report for specialty growth, Other-segment profit, and Global Medical Products costs. A guidance reduction or repeated misses would be a signal to reduce exposure; continued delivery would support holding through the longer-term mix shift.